Bullish on the outlook for LH‘s Covance Drug Development operation and lower risk in the diagnostic business, Deutsche Bank’s Dan Leonard upgrades Labcorp to Buy from Hold.
His Street-high price target of $220 suggests 31% upside.
The average Sell-Side rating for Labcorp is Buy/Outperform, but the Quant Rating is Neutral.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.